Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Thyroid Disorders

Therapeutic area intelligence for Thyroid Disorders with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 7
Catalysts: 0
Companies: 4

Companies

Alembic Pharmaceuticals →

CEDIPROF INC. →

Macleods Pharmaceuticals →

Madrigal Pharmaceuticals →

Assets

Recent signals(7)

RegulatoryAugust 3, 2026

FDA Accepts Supplement for LEVO-T (Levothyroxine Sodium)

The FDA has accepted a supplemental application for LEVO-T, a levothyroxine sodium product, from CEDIPROF INC.

RegulatoryJuly 30, 2026

FDA Accepts Supplemental NDA for REZDIFFRA (Resmetirom) by Madrigal

The FDA has accepted a supplemental NDA for REZDIFFRA, indicating progress in its regulatory pathway.

RegulatoryJuly 29, 2026

FDA Accepts Supplemental NDA for Rezdiffra (Resmetirom) by Madrigal

The FDA has accepted a supplemental NDA for Rezdiffra, indicating ongoing development and potential market entry.

StrategyJuly 19, 2026

FDA Grants Approval for Levothyroxine Sodium ANDA216370 by Alembic

The FDA has granted approval for Alembic's ANDA216370 for Levothyroxine Sodium.

StrategyJuly 17, 2026

FDA Grants AP Status for Levothyroxine Sodium ANDA211417

The FDA has granted approval status (AP) for ANDA211417, a generic formulation of Levothyroxine Sodium by Macleods Pharmaceuticals.

RegulatoryJuly 12, 2026

FDA Accepts Supplemental Application for LEVO-T by CEDIPROF INC.

The FDA has accepted a supplemental application for LEVO-T, a levothyroxine sodium product, from CEDIPROF INC.

RegulatoryJuly 9, 2026

FDA Approves Supplemental Application for Levothyroxine Sodium by Fresenius Kabi

The FDA has approved a supplemental application for Levothyroxine Sodium submitted by Fresenius Kabi.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Thyroid Disorders →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.